VOSE vs. MOSE in EUS-FNB for Pancreatic Masses

November 15, 2026 updated by: Ruijin Hospital

Comparison of Specimen Quality Using Visual On-Site Evaluation Versus Macroscopic On-Site Evaluation in Endoscopic Ultrasound-Guided Fine Needle Biopsy of Solid Pancreatic Masses: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Trial

The primary endpoint of this study was to evaluate whether the histopathological diagnostic accuracy of VOSE EUS-FNB using 22-gauge (22G) Franseen or 22G Trident (Trident™) needles is non-inferior to that of MOSE EUS-FNB in pancreatic solid masses. The secondary endpoints included diagnostic sensitivity, diagnostic specificity, median number of needle passes, puncture time, and cytological diagnostic accuracy.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

472

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200025
        • Ruijin hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age above 18 years, male or female.
  • Presence of a solid pancreatic mass detected by CT, MRI, PET-CT, or EUS, and scheduled for EUS-FNB for diagnostic purposes.
  • Provision of signed written informed consent.

Exclusion Criteria:

  • Contraindications to endoscopy, such as severe cardiovascular or cerebrovascular diseases.
  • Coagulation disorders (International Normalized Ratio [INR] ≥ 1.5, platelet count ≤ 50 × 10^9/L) or current use of anticoagulant or antiplatelet medications.
  • Confirmed or suspected pregnancy.
  • Pathological diagnosis has already been established by other methods.
  • Refusal to participate in the study, current participation in another clinical trial, or participation in another clinical trial within 60 days prior to enrollment.
  • Any other conditions that preclude the performance of EUS-FNB.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: VOSE Group (Visual On-Site Evaluation)

Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and visible tissue cores are placed into formalin for visual grading. If no "red mixed specimen" is observed, additional passes are performed up to 3 passes. The number of passes and puncture time are recorded.

VOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide. Visible tissue cores are placed into a formalin vial, gently shaken to dissolve blood, and visually graded with photographic recording. If the first-pass specimen is not a "red mixed specimen," additional passes are performed until a "red mixed specimen" appears or a maximum of 3 passes is reached.

Active Comparator: MOSE Group (Macroscopic On-Site Evaluation)

Patients undergo EUS-FNB using 22G Franseen or 22G Trident needles. The first pass specimen is pushed onto a slide, and the macroscopic visible core (MVC) length is measured. If the MVC is < 10mm, additional passes are performed until the total MVC is ≥ 10mm or up to 3 passes. The number of passes and puncture time are recorded.

MOSE group:During the EUS-FNB procedure, the first-pass specimen is pushed onto a slide, and the length of the macroscopic visible core (MVC) is measured. If the total MVC length is less than 10 mm, additional passes are performed until the total MVC is ≥ 10 mm or a maximum of 3 passes is reached.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Histopathological diagnostic accuracy
Time Frame: Within 30 days after the EUS-FNB procedure

The diagnostic accuracy of histopathological tissue obtained by EUS-FNB in the VOSE group compared to the MOSE group, using the final surgical pathology or clinical/radiological follow-up as the gold standard.

Within 30 days after the EUS-FNB procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic sensitivity
Time Frame: Within 30 days after the EUS-FNB procedure

The diagnostic sensitivity of VOSE and MOSE groups compared to the final gold standard diagnosis.

Within 30 days after the EUS-FNB procedure
Diagnostic specificity
Time Frame: Within 30 days after the EUS-FNB procedure

The diagnostic specificity of VOSE and MOSE groups compared to the final gold standard diagnosis.

Within 30 days after the EUS-FNB procedure
Median number of needle passes
Time Frame: During the EUS-FNB procedure

The number of needle passes required to obtain adequate tissue samples (until a "red mixed specimen" or MVC ≥ 10mm is observed, up to 3 passes).

During the EUS-FNB procedure
Puncture time
Time Frame: During the EUS-FNB procedure

The duration of the puncture procedure (from the start of the first needle pass to the end of sampling).

During the EUS-FNB procedure
Cytological diagnostic accuracy
Time Frame: Within 30 days after the EUS-FNB procedure

The diagnostic accuracy of liquid-based cytology obtained from residual specimens in VOSE and MOSE groups, compared to the final gold standard diagnosis.

Within 30 days after the EUS-FNB procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2026

Primary Completion (Estimated)

May 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

November 15, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RJ2026164
  • 82570763 (Other Grant/Funding Number: National Nature Science Foundation of China)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe